ImmuneBridge, a San Francisco, California-based biotechnology company that develops allogeneic cell-based drugs, raised $12M in Seed funding.
The round was co-led by Insight Partners and M Ventures, with participation from One Way Ventures and Gaingels. Cheryl Zimberlin, Investment Director at M Ventures, and Dylan Morris, Managing Director at Insight Partners have joined ImmuneBridge’s Board of Directors.
The company intends to use the funds to build a screening dataset for indication-optimized NK cells and generate pre-clinical data for a lead product.
Co-founded by Peretz Partensky and Jesse Cotari, ImmuneBridge is developing allogeneic cell drugs for curative cancer therapies, starting with NK cell-based immunotherapies. Its proprietary expansion technology amplifies cord blood-derived immune stem cells while maintaining full immune multipotency to create a consistent and abundant cell source for immunotherapies. The company’s scientific approach leverages this expansion technology together with the benefits of cord blood to enable screening and selection for cancer-fighting cells.
FinSMEs
12/04/2023